|
1
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26 (Suppl 5):v56–v68. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs. gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sinn M, Bahra M, Liersch T, Gellert K,
Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau
BM, et al: CONKO-005: Adjuvant chemotherapy with gemcitabine plus
erlotinib versus gemcitabine alone in patients after R0 resection
of pancreatic cancer: A multicenter randomized phase III trial. J
Clin Oncol. 35:3330–3337. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gbolahan OB, Tong Y, Sehdev A, O'Neil B
and Shahda S: Overall survival of patients with recurrent
pancreatic cancer treated with systemic therapy: A retrospective
study. BMC Cancer. 19(468)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tuveson DA, Shaw AT, Willis NA, Silver DP,
Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, et
al: Endogenous oncogenic K-ras(G12D) stimulates proliferation and
widespread neoplastic and developmental defects. Cancer Cell.
5:375–387. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ying H, Kimmelman AC, Lyssiotis CA, Hua S,
Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff
JL, et al: Oncogenic Kras maintains pancreatic tumors through
regulation of anabolic glucose metabolism. Cell. 149:656–670.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Junttila MR, Karnezis AN, Garcia D,
Madriles F, Kortlever RM, Rostker F, Brown Swigart LB, Pham DM, Seo
Y, Evan GI and Martins CP: Selective activation of p53-mediated
tumour suppression in high-grade tumours. Nature. 468:567–571.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Burgess MR, Hwang E, Mroue R, Bielski CM,
Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L,
et al: KRAS Allelic imbalance enhances fitness and modulates MAP
kinase dependence in cancer. Cell. 168:817–829.e15. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sobin LH, Gospodarowicz MK and Wittekind C
(eds): International Union Against Cancer (UICC): TNM
Classification of Malignant Tumours. 7th edition, Wiley-Blackwell,
Oxford, 2009.
|
|
13
|
Okusaka T, Nakamura M, Yoshida M, Kitano
M, Uesaka K, Ito Y, Furuse J, Hanada K and Okazaki K: Committee for
Revision of Clinical Guidelines for Pancreatic Cancer of the Japan
Pancreas Society. Clinical practice guidelines for pancreatic
cancer 2019 from the Japan pancreas society: A synopsis. Pancreas.
49:326–335. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sodir NM, Kortlever RM, Barthet VJA,
Campos T, Pellegrinet L, Kupczak S, Anastasiou P, Swigart LB,
Soucek L, Arends MJ, et al: MYC instructs and maintains pancreatic
adenocarcinoma phenotype. Cancer Discov. 10:588–607.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mueller S, Engleitner T, Maresch R,
Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R,
Zwiebel M, Strong A, et al: Evolutionary routes and KRAS dosage
define pancreatic cancer phenotypes. Nature. 554:62–68.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015.PubMed/NCBI View
Article : Google Scholar
|
